761 / 1631
RELEVANCE: TREATMENT-EMERGENT ADVERSE EVENTS
TEAEs for R
2
(n = 507), %
TEAEs for R-chemo (n = 503), %
Data cut-off31May2017. Includesany-gradeTEAEs (≥15%) and select AEs of interest as assessed per NCI CTCAE v4.03.
*HematologicAEs were based on laboratorytests; all anemia events were grade 1. Cutaneous reactions included preferredterms from skin and subcutaneous tissue disorders (includingrash), gastrointestinal
disorders,
0
Grade 3/4
Any grade
0
20
40
60
80
100
Any event
Neutropenia*
Anemia*
Thrombocytopenia*
Nausea
Constipation
Fatigue
Asthenia
Cutaneous reactions*
- Rash
Diarrhea
Vomiting
Bronchitis
Peripheral neuropathy
Pyrexia
Cough
Back pain
Abdominal pain
Pruritus
Alopecia
Febrile neutropenia
Tumor flare reaction
Tumor lysis syndrome
TEAEs, %
20
40
60
80
100
TEAEs, %
general disorders and administrationsite conditions,infectionsand infestations,and reproductivesystem and breast disorders.
Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R
2
) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWithPreviously Untreated Follicular
Lymphoma. Oral presentationat: AmericanSociety of Clinical Oncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.